Mese Sevim, Allahverdiyeva Aytaj, Onel Mustafa, Uysal Hayriye Kırkoyun, Agacfidan Ali
Istanbul Medicine Faculty, Department of Virology and Basic Immunology, Istanbul University, Istanbul 34093, Turkey.
Infect Dis Rep. 2024 Oct 10;16(5):992-1004. doi: 10.3390/idr16050079.
Respiratory viruses significantly impact public health, contributing to high morbidity and mortality rates in both children and adults. This study evaluates the distribution and incidence of respiratory tract viruses in our hospital from 2019 to 2022, focusing on changes post-COVID-19 pandemic. Utilizing molecular methods, we analyzed nasopharyngeal swabs with the FTD Respiratory Pathogens 21 kit and the QIAStat Dx Respiratory Panel kit at Istanbul Faculty of Medicine. A total of 1186 viruses were detected in 2488 samples (47.6% of the total) examined with the FTD Respiratory Pathogens 21 kit between 2019 and 2022. It was determined that the detection rates were 52.8% in 2019, 44.3% in 2020, 50.0% in 2021, and 40.0% in 2022. Notable changes in prevalence were observed for pandemic influenza A (IAV-H1N1pdm2009), parainfluenza virus (PIV)-3, rhinovirus (RV), and respiratory syncytial virus (RSV)-A/B ( < 0.05). RV consistently showed the highest detection rates across all years (17.6% to 7.9%). Additionally, 1276 viruses were detected in 1496 samples using the QIAStat DX kit, with 91.3% positivity in 2021 and 78.6% in 2022, highlighting the kit's effectiveness in rapid diagnosis. This study enhances understanding of respiratory virus epidemiology during and after the pandemic, emphasizing the need for ongoing surveillance and strategic public health measures to address the evolving landscape of respiratory infections.
呼吸道病毒对公众健康有重大影响,导致儿童和成人的发病率和死亡率居高不下。本研究评估了2019年至2022年我院呼吸道病毒的分布和发病率,重点关注新冠疫情后的变化。我们在伊斯坦布尔医学院采用分子方法,使用FTD呼吸道病原体21试剂盒和QIAStat Dx呼吸道检测试剂盒对鼻咽拭子进行分析。在2019年至2022年期间,使用FTD呼吸道病原体21试剂盒检测的2488份样本(占总数的47.6%)中共检测到1186种病毒。确定2019年的检出率为52.8%,2020年为44.3%,2021年为50.0%,2022年为40.0%。观察到甲型大流行性流感(IAV-H1N1pdm2009)、副流感病毒(PIV)-3、鼻病毒(RV)和呼吸道合胞病毒(RSV)-A/B的流行率有显著变化(<0.05)。RV在所有年份的检出率始终最高(17.6%至7.9%)。此外,使用QIAStat DX试剂盒在1496份样本中检测到1276种病毒,2021年的阳性率为91.3%,2022年为78.6%,突出了该试剂盒在快速诊断方面的有效性。本研究增进了对疫情期间及之后呼吸道病毒流行病学的了解,强调了持续监测和战略性公共卫生措施的必要性,以应对不断变化的呼吸道感染形势。